他汀治疗PCI患者残余胆固醇与炎症风险对比
随访1年发现,孤立残余炎症风险者MACE率最高(5.1%),残余炎症风险与MACE独立相关(aHR 1.78),而孤立残余胆固醇风险无独立关联(aHR 1.01)。
要点
- 他汀治疗PCI患者中,残余炎症风险(hs-CRP≥2 mg/L)与1年MACE风险独立相关。
- 孤立残余胆固醇风险(LDL-C≥70 mg/dL)未显示与MACE独立关联。
- 残余炎症风险者MACE率最高(5.1%),联合风险次之。
核心结论
- 在他汀治疗的PCI患者中,残余炎症风险而非胆固醇风险与随访期间MACE风险增加相关。
主要发现
- 随访1年,孤立残余炎症风险组MACE率最高(5.1%),其次为联合风险组、无残余风险组和孤立残余胆固醇风险组。
- 残余炎症风险组较无残余风险组MACE风险升高(aHR 1.78,95%CI 1.36-2.33,P<0.001)。
- 联合残余胆固醇和炎症风险组MACE风险亦升高(aHR 1.56,95%CI 1.19-2.04,P=0.001)。
关键数值与推荐
- 残余胆固醇风险定义为LDL-C≥70 mg/dL,残余炎症风险定义为hs-CRP≥2 mg/L。
- 排除急性心肌梗死、癌症、入院时未接受他汀治疗或hs-CRP>10 mg/L的患者。
- 主要终点为PCI术后1年主要不良心血管事件(MACE),包括全因死亡、自发性心肌梗死和卒中。
临床怎么用
- 对于他汀治疗的PCI患者,应关注hs-CRP评估残余炎症风险,而非仅关注LDL-C。
- hs-CRP≥2 mg/L提示需考虑抗炎治疗策略以降低MACE风险。
局限性
- 单中心回顾性研究,结果需多中心前瞻性验证。
- 未报告盲法或混杂因素控制细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Elevated LDL-cholesterol levels and inflammation, as assessed by high-sensitivity C-reactive protein, correlate with cardiovascular risk. However, data on the relative impact of residual LDL-cholesterol and inflammatory risk among statin-treated patients undergoing percutaneous coronary intervention (PCI) is lacking. Hence, this study aimed to investigate the impact of residual cholesterol/inflammatory risk in patients on statin therapy undergoing PCI. METHODS: From 2012 to 2022, patients at a tertiary centre undergoing PCI were analysed. Patients were stratified according to LDL-cholesterol (≥70 vs <70 mg/dL) and high-sensitivity C-reactive protein (≥2 vs <2 mg/L) levels: no residual cholesterol or inflammatory risk, residual cholesterol risk, residual inflammatory risk, and combined residual cholesterol and inflammatory risk. Patients presenting with acute myocardial infarction, cancer, no statin treatment at admission, or high-sensitivity C-reactive protein levels >10 mg/L were excluded. The primary endpoint was major adverse cardiovascular events (MACEs), defined as the composite of all-cause mortality, spontaneous myocardial infarction, and stroke 1 year after the index PCI. RESULTS: A total of 15 494 patients were included. After 1-year follow-up, individuals with isolated residual inflammatory risk had the highest MACE rate (5.1%), followed by patients with combined cholesterol and inflammatory risk, no residual risk, and isolated residual cholesterol risk. After multivariable Cox regression analysis, patients with residual inflammatory risk had a 1.8-fold higher risk for MACE (adjusted hazard ratio: 1.78, 95% confidence interval 1.36-2.33, P < .001) compared with those with no residual cholesterol or inflammatory risk. This was similar in patients with combined residual cholesterol and inflammatory risk (adjusted hazard ratio: 1.56, 95% confidence interval 1.19-2.04, P = 0.001). Of note, no independent association of isolated residual cholesterol risk (adjusted hazard ratio: 1.01, 95% confidence interval .76-1.35, P-value = .920) with MACE was noted (P-trend across all groups <.001). CONCLUSIONS: Among statin-treated patients undergoing PCI, residual inflammation but not cholesterol risk was associated with an increased risk of MACE during follow-up.
引用
- Bay B, Tanner R, Gao M, et al. Residual cholesterol and inflammatory risk in statin-treated patients undergoing percutaneous coronary intervention†. Eur Heart J. 2025. PMID: 40208236. doi:10.1093/eurheartj/ehaf196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。